Grace Therapeutics (GRCE) Total Current Liabilities (2017 - 2026)
Grace Therapeutics (GRCE) posted Total Current Liabilities of $2.1 million for Q1 2026, up 67.13% sequentially from $1.3 million in Q4 2025, and up 11.19% YoY from $1.9 million in Q1 2025.
Grace Therapeutics (GRCE) Total Current Liabilities (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Total Current Liabilities for 10 years, with the latest figure at $2.1 million in Q1 2026.
- Quarterly Total Current Liabilities rose 11.19% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 11.19% YoY) and the FY2026 annual result came in at $2.1 million, up 11.19% from the prior year.
- Total Current Liabilities improved to $2.1 million in Q1 2026 per GRCE's latest filing, from $1.3 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $3.8 million in Q3 2022 and troughed at $1.2 million in Q3 2025.
- A 5-year average of $2.4 million and a median of $2.1 million in 2026 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 106.46% in 2022, then slumped 63.29% in 2023.
- Over 5 years, Total Current Liabilities stood at $3.4 million in 2022, then tumbled by 48.44% to $1.8 million in 2023, then grew by 11.36% to $2.0 million in 2024, then tumbled by 34.86% to $1.3 million in 2025, then soared by 67.13% to $2.1 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.1 million, $1.3 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | 1.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Mn |
| Mar 31, 2026 | 2.15 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 1.77 Mn |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.97 Mn |
| Mar 31, 2023 | 3.41 Mn |
| Dec 31, 2022 | 3.43 Mn |
| Sep 30, 2022 | 3.81 Mn |
| Jun 30, 2022 | 3.71 Mn |
| Mar 31, 2022 | 3.26 Mn |
| Dec 31, 2021 | 2.90 Mn |
| Sep 30, 2021 | 4.48 Mn |